ESERINE CHEMICAL STRUCTURE PDF

State: Solid; Experimental Properties data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. The IUPHAR/BPS Guide to Pharmacology. physostigmine ligand page. Quantitative data and Calculated Physico-chemical Properties Click here for help. Physostigmine, as the salicylate salt, is being developed as a drug for . From these structural studies emerges a view of the molecular basis of.

Author: Mezil Zulucage
Country: Vietnam
Language: English (Spanish)
Genre: Health and Food
Published (Last): 21 July 2006
Pages: 383
PDF File Size: 7.74 Mb
ePub File Size: 6.54 Mb
ISBN: 366-4-33609-640-3
Downloads: 84831
Price: Free* [*Free Regsitration Required]
Uploader: Voodoobei

A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used chemcial central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Physostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor which effectively increases strufture concentration of acetylcholine at the sites of cholinergic transmission. Physostigmine is used to treat glaucoma. Because it crosses the blood-brain barrier, it is also used to treat the central nervous system effects of atropine overdose and other anticholinergic drug overdoses. Physostigmine can reverse both central and peripheral anticholinergia.

Physostigmine inhibits acetylcholinesterase, the enzyme responsible for the breakdown of used acetylcholine. By interfering with the metabolism of acetylcholine, physostigmine indirectly stimulates both nicotinic and muscarinic receptors due to the consequential increase in available acetylcholine at the synapse.

Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain. Kurys, “4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof.

Patent US, issued September, Drug created on June 13, Physostigmine Targets 3 Biointeractions 1. Drug Interaction Acebutolol Physostigmine may increase the bradycardic activities of Acebutolol. Acetylcholine The risk or severity of adverse effects can be increased when Physostigmine is combined with Acetylcholine.

Aclidinium The therapeutic efficacy of Aclidinium can be decreased when used in combination with Physostigmine. Agmatine The therapeutic efficacy of Agmatine can be decreased when used in combination with Physostigmine.

Alcuronium The therapeutic efficacy of Alcuronium can be decreased when used in combination with Physostigmine. Aldosterone The therapeutic efficacy of Physostigmine can be decreased when used in combination with Aldosterone. Alprenolol Physostigmine may increase the bradycardic activities of Alprenolol. Amifampridine The risk or severity of wserine effects stricture be increased when Physostigmine is combined with Amifampridine.

Amikacin The therapeutic efficacy of Physostigmine can be decreased when used in combination with Amikacin. Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Cbemical. Amobarbital The therapeutic efficacy of Amobarbital can be decreased when used in combination with Physostigmine. Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Physostigmine.

Anisodamine Physostigmine may increase the bradycardic activities of Anisodamine.

Anisotropine Methylbromide The therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Physostigmine. Apramycin The therapeutic efficacy of Physostigmine can be decreased when used in combination with Apramycin. Aprobarbital The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Physostigmine.

  BUCKYBALLS BIG BOOK OF BUCKY VOL 1 PDF

Arbekacin The therapeutic efficacy of Physostigmine can be decreased when used in eserin with Arbekacin. Arecoline The risk or severity of adverse effects can be increased when Physostigmine is combined with Arecoline. Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased eswrine used in combination with Physostigmine. Arotinolol Physostigmine may increase the bradycardic activities of Arotinolol.

Atenolol Physostigmine may increase the bradycardic activities of Atenolol. Atracurium The therapeutic efficacy of Atracurium can be decreased when used in combination with Physostigmine. Atracurium besylate The therapeutic esegine of Atracurium besylate can be decreased when cnemical in combination with Physostigmine. Atropine The therapeutic efficacy of Atropine can be decreased when used in combination with Physostigmine. Bambuterol Physostigmine may increase the neuromuscular blocking activities of Bambuterol.

Barbital The therapeutic efficacy of Barbital can be decreased when used in combination with Physostigmine. Barbituric acid derivative The therapeutic efficacy of Barbituric acid derivative can be decreased when used in combination with Physostigmine.

physostigmine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY

Beclomethasone dipropionate The therapeutic efficacy of Physostigmine can be decreased when used in combination with Beclomethasone dipropionate.

Befunolol Physostigmine may increase the bradycardic activities of Befunolol. Bekanamycin The therapeutic efficacy of Physostigmine can be decreased when used in combination with Bekanamycin. Benactyzine The therapeutic efficacy of Benactyzine can be decreased when used cemical combination with Physostigmine.

Benzatropine The therapeutic efficacy of Benzatropine can be decreased when used in combination with Physostigmine. Benzilone The therapeutic efficacy of Benzilone can be decreased when used in combination with Physostigmine. Benzquinamide The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Physostigmine.

Betamethasone The therapeutic efficacy of Physostigmine can be decreased when used in combination with Betamethasone.

Betamethasone phosphate The therapeutic efficacy of Physostigmine can be decreased cnemical used in combination with Betamethasone phosphate. Betaxolol Physostigmine may increase the bradycardic activities of Betaxolol. Bethanechol The risk or severity structhre adverse effects can be increased when Physostigmine is combined with Bethanechol. Bevantolol Physostigmine may increase the bradycardic activities of Bevantolol.

Bevonium The therapeutic efficacy of Bevonium can be decreased when used in combination with Physostigmine. Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Physostigmine.

Bisoprolol Physostigmine may increase the bradycardic activities of Bisoprolol. Bopindolol Physostigmine may increase the bradycardic activities of Bopindolol. Bornaprine The therapeutic efficacy of Bornaprine can be decreased when used in combination with Physostigmine. Brompheniramine The therapeutic efficacy of Brompheniramine can cgemical decreased when used in combination with Physostigmine. Bucindolol Physostigmine may increase the bradycardic activities of Bucindolol.

Buclizine The therapeutic efficacy of Buclizine can be decreased when used in combination with Physostigmine. Budesonide The therapeutic efficacy of Physostigmine can be decreased when used in combination with Budesonide. Bufuralol Physostigmine may increase the bradycardic activities of Bufuralol. Bupranolol Physostigmine cuemical increase the bradycardic activities of Bupranolol.

Bupropion The therapeutic efficacy of Bupropion can be decreased when used in combination with Physostigmine. Butabarbital The therapeutic efficacy of Butabarbital can be decreased when used in combination with Physostigmine. Butalbital The therapeutic efficacy of Butalbital can be decreased when used in combination with Physostigmine.

  AQIDAH SHAHIHAH PDF

Butethal The therapeutic efficacy of Butethal can be decreased when used in combination with Physostigmine. Butylscopolamine The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Physostigmine. Camylofin The therapeutic efficacy of Camylofin can be decreased when used in combination with Physostigmine. Capreomycin The therapeutic efficacy of Physostigmine can be decreased when used in combination with Capreomycin.

Carbamoylcholine The risk or severity of adverse effects can be increased when Physostigmine is shructure with Carbamoylcholine. Carvedilol Physostigmine may increase the bradycardic activities of Carvedilol. Celiprolol Physostigmine may increase the bradycardic activities of Celiprolol. Cetirizine The therapeutic efficacy of Cetirizine can be decreased when used in combination with Physostigmine.

Cevimeline The risk or severity of adverse effects can be increased when Physostigmine is combined with Cevimeline. Chloroprocaine The therapeutic efficacy of Chloroprocaine can be decreased when used in combination with Physostigmine. Chlorphenoxamine The therapeutic efficacy of Chlorphenoxamine can be decreased shructure used in combination with Physostigmine. Chlorpromazine The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Physostigmine.

Chlorprothixene The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Physostigmine. Ciclesonide The therapeutic efficacy of Physostigmine can be decreased when used in combination with Ciclesonide.

Cisatracurium The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Physostigmine. Clevidipine Physostigmine may increase the neuromuscular blocking activities of Clevidipine. Eerine The therapeutic efficacy of Clidinium can be decreased when used in combination with Physostigmine. Clobetasol The therapeutic efficacy of Physostigmine can chemiacl decreased when used in combination with Clobetasol.

(-)-Physostigmine | C15H21N3O2 – PubChem

Clocortolone acetate The therapeutic efficacy of Physostigmine can be decreased when chekical in combination with Clocortolone acetate. Cloprednol The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cloprednol.

Cloranolol Physostigmine may increase the bradycardic activities of Cloranolol. Clozapine The therapeutic efficacy of Clozapine can be decreased when used in combination with Physostigmine.

Cocaine The therapeutic efficacy of Cocaine can be decreased when used in combination with Physostigmine. Corticotropin The therapeutic efficacy of Physostigmine can be decreased when used in combination with Corticotropin. Cortisone The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cortisone. Cortisone acetate The therapeutic efficacy of Physostigmine can be decreased when used in combination with Cortisone acetate.

Physostigmine

Cortivazol The therapeutic efficacy of Physostigmine can strufture decreased when used in combination with Cortivazol. Cycrimine The therapeutic efficacy of Cycrimine can be decreased when used in combination with Physostigmine. Cyproheptadine The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Physostigmine.

Darifenacin The therapeutic efficacy of Darifenacin can be decreased when esfrine in combination with Physostigmine. Deflazacort The therapeutic efficacy of Physostigmine can be decreased when used in combination with Deflazacort. Desipramine The therapeutic efficacy of Desipramine can be decreased when used in combination with Physostigmine.